NCT07058012
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07058012
Title A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) (EMPIRE)
Acronym EMPIRE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NSABP Foundation Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Florida RECRUITING Gainesville Florida 32611 United States Details
University of Iowa - Holden Comprehensive Cancer Center RECRUITING Iowa City Iowa 52242 United States Details
University of Kansas Cancer Center RECRUITING Kansas City Kansas 66160 United States Details
Missouri Baptist RECRUITING St Louis Missouri 63131 United States Details
First Health of the Carolinas RECRUITING Pinehurst North Carolina 28374 United States Details
Allegheny General Hospital RECRUITING Pittsburgh Pennsylvania 15212 United States Details
Ballad Health Cancer Center - Kingsport RECRUITING Kingsport Tennessee 37660 United States Details
Bon Secours St. Francis Medical Center RECRUITING Midlothian Virginia 23114 United States Details
Virginia Commonwealth University - Massey RECRUITING Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field